Breaking News Instant updates and real-time market news.

NKE

Nike

$59.95

0.85 (1.44%)

, FB

Facebook

$164.43

-0.1 (-0.06%)

08:28
07/22/17
07/22
08:28
07/22/17
08:28

AllianceBernstein's Caruso sees EPS as 'poor' report card, Barron's says

Frank Caruso, the chief investment officer of AllianceBernstein's (AB) U.S. growth strategies, believes in buying growth companies and not growth stocks, with its AB Large Cap Growth fund results confirming his skepticism of "timeworn investment metrics," Sarah Max writes in this week's edition of Barron's. To help identify and analyze growth companies, Caruso and his team developed a "persistent return model," which looks at more than a handful of factors, including return on assets, the report noted, adding that among the top holdings are Nike (NKE), Facebook (FB), and Intuitive Surgical (ISRG). While most of the fund's assets are in "wheelhouse names," Caruso also makes smaller investments in earlier-stage growth companies, such as Arista Networks (ANET), Barron's added.Reference Link

NKE

Nike

$59.95

0.85 (1.44%)

FB

Facebook

$164.43

-0.1 (-0.06%)

ISRG

Intuitive Surgical

$927.47

-44.26 (-4.55%)

ANET

Arista Networks

$152.92

-3.88 (-2.47%)

AB

AllianceBernstein

$24.75

0.1 (0.41%)

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

  • 16

    Aug

  • 17

    Aug

  • 21

    Aug

  • 13

    Sep

NKE Nike
$59.95

0.85 (1.44%)

07/20/17
07/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Jay Sole saying the window to buy Nike is closing as earnings and North America sales growth rates are likely troughing. 2. B&G Foods (BGS) upgraded to Buy from Neutral at Citi with analyst Cornell Burnett saying the second quarter should mark a positive inflection in organic sales after five consecutive quarters of declines. 3. HP Inc. (HPQ) upgraded to Outperform from Sector Perform at RBC Capital with analyst Amit Daryanani saying he sees a "string of beats/raises" ahead amid stabilizing PC fundamentals and market share gains as Lenovo struggles. 4. Royal Caribbean (RCL) upgraded to Overweight from Neutral at JPMorgan with analyst Joseph Greff saying he views the current valuation as "undemanding" and notes his recent channel checks suggest continued good operating momentum. 5. Buffalo Wild Wings (BWLD) upgraded to Neutral from Underperform at Wedbush with analyst Nick Setyan saying investors understand that the company could report weaker than expected results and his other concerns about the company "are well understood." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/17
MSCO
07/19/17
UPGRADE
Target $68
MSCO
Overweight
Morgan Stanley says buy Nike before window closes, upgrades shares
Morgan Stanley analyst Jay Sole upgraded Nike to Overweight from Equal Weight and raised his price target for the shares to $68 from $56 following today's market close. The stock closed the day up 12c to $57.77. The window to buy Nike is closing as earnings and North America sales growth rates are likely troughing, Sole tells investors in a research note. The analyst pegs the stock's risk/reward at three-to-one to the upside. He believes Nike's new products like Air VaporMax and quicker speed-to-market will reverse the headwinds it has experienced over the past 18 months.
07/19/17
MSCO
07/19/17
UPGRADE
MSCO
Overweight
Nike upgraded to Overweight from Equal Weight at Morgan Stanley
07/18/17
NEED
07/18/17
INITIATION
NEED
Hold
Nike initiated with a Hold at Needham
FB Facebook
$164.43

-0.1 (-0.06%)

07/17/17
MKMP
07/17/17
NO CHANGE
Target $180
MKMP
Buy
Facebook consensus forecasts looks overly conservative, says MKM Partners
MKM Partners analyst Rob Sanderson said anecdotes from ad agencies and partners suggest that strong trends in social media spending and allocation to Facebook have continued, leading him to believes that consensus forecasts for the company's upcoming Q2 report seem overly conservative. Sanderson reiterates a Buy rating and $180 price target on Facebook shares ahead of the Q2 report, which is scheduled for July 26.
07/19/17
GSCO
07/19/17
NO CHANGE
Target $180
GSCO
Buy
Facebook Q2 checks positive, innovation to drive results, says Goldman Sachs
Goldman analyst Heather Bellini said Facebook Q2 field checks were universally positive, suggesting the pace of innovation is accelerating on both the consumer product and the ad tech stack. The analyst said advertisers are achieving higher returns and expects increased video content from publishers and recent advertising on Messenger to driver higher CPMs, and higher available ad inventory overall, increasing her confidence in sustained revenue growth. Bellini raised CY17 earnings to $4.96, versus consensus of $4.85, and raised CY18 earnings to $5.88, versus consensus of $5.98. The analyst rates Facebook a Buy with a $180 price target.
07/19/17
NEED
07/19/17
NO CHANGE
Target $185
NEED
Buy
Facebook price target raised to $185 from $165 at Needham
Needham analyst Laura Martin raised her price target for Facebook (FB) to $185 from $165 as user growth has outpaced her estimates and her channel checks indicate more robust advertising revenue growth than she previously projected, owing to more video ads, faster Instagram revenue growth, and lower competition from Snap (SNAP) than she had previously projected. The analyst now believes Facebook is "becoming the de facto near-monopoly mobile choice" for brands and direct response advertisers. Martin reiterates a Buy rating on Facebook's shares.
07/19/17
MOFT
07/19/17
NO CHANGE
Target $11
MOFT
Sell
Snap still has room to fall, says MoffettNathanson
offettNathanson analyst Michael Nathanson said Snap (SNAP) still has room to fall and sees two near-term catalysts that can push shares towards his $11 price target. Nathanson said its a "scary admission" by Snap that disappointing growth is due to seasonality and said its seems like an artful warning to take down estimates for Q3. Further, the analyst believes Snap's lock-up expiration on July 30 could drive a double digit sell-off, if you use Facebook (FB) and Twitter (TWTR) histories as a guide. Nathanson rates Snap a Sell.
ISRG Intuitive Surgical
$927.47

-44.26 (-4.55%)

07/18/17
RBCM
07/18/17
NO CHANGE
RBCM
Intuitive Surgical should deliver beat and raise results, says RBC Capital
RBC Capital analyst Brandon Henry expects Intuitive Surgical to report stronger than expected Q2 results and raise its procedure growth guidance. However, the analyst says that expectations are high heading into the results, and he keeps a Sector Perform rating on the shares.
07/21/17
LEHM
07/21/17
NO CHANGE
Target $1000
LEHM
Overweight
Intuitive Surgical price target raised to $1,000 from $870 at Barclays
Barclays analyst Matthew Taylor raised his price target for Intuitive Surgical to $1,000 saying the company reported a "robust" Q2 with procedure growth of 16% versus the consensus of 13%. Further, new box placements accelerated with notable strength in the U.S. and some contribution from the new X system, Taylor tells investors in a post-earnings research note. He lists valuation and the potential for competition "down the road" as his only concerns. The analyst keeps an Overweight rating on Intuitive Surgical.
07/21/17
JPMS
07/21/17
NO CHANGE
Target $1050
JPMS
Overweight
Intuitive Surgical price target raised to $1,050 from $950 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Intuitive Surgical to $1,050 saying "robust growth" in both systems and procedures drove strong Q2 results. The company's growth curve showing no signs of slowing, the analyst tells investors in a research note. He reiterates an Overweight rating on Intuitive shares.
07/21/17
ADAM
07/21/17
NO CHANGE
Target $1000
ADAM
Hold
Intuitive Surgical fundamentals strong but valuation high, says Canaccord
Canaccord analyst Jason Mills noted Intuitive Surgical reported another "stellar" quarter with robust volume growth. The analyst said the company is firing on all cylinders and its valuation is priced for perfection, leaving little room for error. Mills raised his price target to $1,000 from $870 on Intuitive surgical shares and said his reason for a Hold rating is its valuation, not fundamentals. He also believes investors are already paying for Intuitive's pipeline through 2018.
ANET Arista Networks
$152.92

-3.88 (-2.47%)

06/01/17
WELS
06/01/17
NO CHANGE
WELS
Arista Networks wins another critical victory against Cisco, says Wells Fargo
Wells Fargo said Arista Networks (ANET) won another critical victory against Cisco (CSCO) in the '945 ITC patent case. The US Patent Trial and Appeal Board invalidated Cisco's '668 patent, which was one of the two patents in the '945 case Arista was found to violated. The firm's analyst said Arista no longer faces a potential injunction that would have prevented it from importing international components and or systems, eliminates the need for workarounds, and prevents Cisco from suing Arista for monetary damages.
06/02/17
OPCO
06/02/17
NO CHANGE
Target $160
OPCO
Outperform
Arista Networks legal risk is dissipating, says Oppenheimer
Oppenheimer analyst Ittai Kidron says Arista Networks' (ANET) legal risk is dissipating after the Patent and Trial Appeal Board yesterday issued a final decision invalidating all relevant claims of one of the Cisco (CSCO) patents involved in the ongoing Arista/Cisco litigation. This follows a May 25 PTAB decision invalidating a different Cisco patent. Taken together, these decisions are a positive for Arista, Kidron tells investors in a research note. He believes the invalidation of these patents eliminates the infringement and the need to develop workarounds. The analyst keeps an Outperform rating on Arista shares with a $160 price target.
06/12/17
NEED
06/12/17
NO CHANGE
Target $175
NEED
Buy
Arista Networks price target raised to $175 on 100G inflection at Needham
Needham analyst Alex Henderson believes Q2 will mark the inflection point in the 100G upgrade cycle, which he thinks will likely result in another acceleration in Arista Networks's Web 2.0 business. Noting that he expects "robust upside" to Arista estimates in 2017 and into 2018, Henderson raised his price target to $175 from $162 and keeps a Buy rating on the shares.
06/15/17
LEHM
06/15/17
NO CHANGE
Target $185
LEHM
Overweight
Arista Networks price target raised to $185 from $161 at Barclays
Barclays analyst Mark Moskowitz raised his price target for Arista Networks (ANET) to $185 citing "fading" litigation risk, improving gross margin and the potential for revenue upside related to the HP Enterprise (HPE) partnership. The analyst believes long-term investors may be taking a fresh look at the shares following the recent favorable ruling from the Patent and Trial Board against Cisco Systems (CSCO). He keeps an Overweight rating on Arista.
AB AllianceBernstein
$24.75

0.1 (0.41%)

06/05/17
SIDC
06/05/17
INITIATION
Target $28
SIDC
Buy
AllianceBernstein initiated with a Buy at Sidoti
Sidoti initiated AllianceBernstein with a Buy and a $28 price target.
04/12/17
BOFA
04/12/17
UPGRADE
BOFA
Buy
AllianceBernstein upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Michael Carrier upgraded AllianceBernstein two notches to Buy from Underperform and raised its price target to $25 from $24 to reflect increased confidence in organic growth outlook and believes with a greater than 8% yield, shares are undervalued.
04/11/17
KBWI
04/11/17
UPGRADE
KBWI
Outperform
AllianceBernstein upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette upgraded AllianceBernstein to Outperform from Market Perform with a $26 price target, citing attractive risk/reward.
12/16/16
BOFA
12/16/16
DOWNGRADE
Target $22
BOFA
Underperform
AllianceBernstein downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Michael Carrier downgraded AllianceBernstein two notches to Underperform and lowered its price target to $22 from $25. The analyst does not expect the company to benefit from U.S. tax reform given its structure and expects a rotation out of fixed income to impact organic growth.

TODAY'S FREE FLY STORIES

SRRA

Sierra Oncology

$1.61

-0.04 (-2.42%)

05:45
11/15/18
11/15
05:45
11/15/18
05:45
Hot Stocks
Sierra Oncology reports preclinical efficacy for SRA737 »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

05:40
11/15/18
11/15
05:40
11/15/18
05:40
Downgrade
Daimler AG rating change  »

Daimler AG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIU

AC Immune

$8.83

-0.15 (-1.67%)

05:39
11/15/18
11/15
05:39
11/15/18
05:39
Hot Stocks
AC Immune awarded third follow-up grant from The Michael J. Fox Foundation »

AC Immune announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

05:38
11/15/18
11/15
05:38
11/15/18
05:38
Hot Stocks
Biohaven enrolls first patient in Phase 3 preventive treatment of migraine trial »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 27

    Nov

FB

Facebook

$144.25

2.06 (1.45%)

, AAPL

Apple

$186.81

-5.42 (-2.82%)

05:36
11/15/18
11/15
05:36
11/15/18
05:36
Periodicals
Facebook CEO ordered staff to use Android phones after Apple criticism, NYT says »

Facebook (FB) CEO Mark…

FB

Facebook

$144.25

2.06 (1.45%)

AAPL

Apple

$186.81

-5.42 (-2.82%)

GOOG

Alphabet

$1,043.53

7.2 (0.69%)

GOOGL

Alphabet Class A

$1,054.06

5.52 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

ABBV

AbbVie

$88.28

0.06 (0.07%)

05:29
11/15/18
11/15
05:29
11/15/18
05:29
Hot Stocks
AbbVie signs DUBs collaboration with Mission Therapeutics »

Mission Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNK

Teekay Tankers

$1.07

0.025 (2.39%)

05:26
11/15/18
11/15
05:26
11/15/18
05:26
Earnings
Teekay Tankers reports Q3 adj. EPS (7c), consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ATUS

Altice USA

$17.71

-0.1 (-0.56%)

05:25
11/15/18
11/15
05:25
11/15/18
05:25
Initiation
Altice USA initiated  »

Altice USA initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGP

Teekay LNG

$14.41

0.29 (2.05%)

05:23
11/15/18
11/15
05:23
11/15/18
05:23
Earnings
Teekay LNG reports Q3 adj. EPS 16c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SUBCY

Subsea 7

$0.00

(0.00%)

05:22
11/15/18
11/15
05:22
11/15/18
05:22
Upgrade
Subsea 7 rating change  »

Subsea 7 upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EXEL

Exelixis

$16.75

0.09 (0.54%)

, IPSEY

Ipsen

$0.00

(0.00%)

05:20
11/15/18
11/15
05:20
11/15/18
05:20
Hot Stocks
Exelixis receives EC approval for Cabometyx tablets »

Exelixis (EXEL) announced…

EXEL

Exelixis

$16.75

0.09 (0.54%)

IPSEY

Ipsen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

  • 14

    Jan

CTTAY

Continental AG

$0.00

(0.00%)

05:19
11/15/18
11/15
05:19
11/15/18
05:19
Downgrade
Continental AG rating change  »

Continental AG downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

VLEEY

Valeo

$0.00

(0.00%)

05:18
11/15/18
11/15
05:18
11/15/18
05:18
Downgrade
Valeo rating change  »

Valeo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,599.16

-32.52 (-1.99%)

05:14
11/15/18
11/15
05:14
11/15/18
05:14
Recommendations
Amazon.com analyst commentary  »

Amazon shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

ATNX

Athenex

$10.28

-1.38 (-11.84%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Upgrade
Athenex rating change  »

Athenex upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

STIM

Neuronetics

$18.58

-3.17 (-14.57%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Recommendations
Neuronetics analyst commentary  »

Neuronetics selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVID

Avid

$5.79

0.19 (3.39%)

04:59
11/15/18
11/15
04:59
11/15/18
04:59
Recommendations
Avid analyst commentary  »

Avid price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$153.45

-3.35 (-2.14%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Initiation
Linde plc initiated  »

Linde plc initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKTX

MarketAxess

$209.85

2.02 (0.97%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
MarketAxess management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Breaking General news story  »

Week of 11/9 EIA Natural…

QLYS

Qualys

$71.92

-0.09 (-0.12%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Qualys to hold analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 09

    Jan

PFG

Principal Financial

$48.29

-0.71 (-1.45%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Principal Financial to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 03

    Dec

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
RBC Capital telecom/data centers analyst to hold a group luncheon »

Telecom & Data…

CNHI

CNH Industrial

$9.81

-0.03 (-0.30%)

, HSY

Hershey

$107.94

-1.24 (-1.14%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
BlackLine to hold a summit »

In The Black 2018:…

CNHI

CNH Industrial

$9.81

-0.03 (-0.30%)

HSY

Hershey

$107.94

-1.24 (-1.14%)

TAP

Molson Coors

$64.75

0.24 (0.37%)

ZEN

Zendesk

$53.12

0.56 (1.07%)

ETP

Energy Transfer Partners

$0.00

(0.00%)

G

Genpact

$29.11

-0.73 (-2.45%)

SAP

SAP

$103.86

0.11 (0.11%)

BL

BlackLine

$38.78

-1.79 (-4.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 26

    Nov

  • 02

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.